These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30877707)

  • 1. Dipeptidyl Peptidase-4 Inhibitors versus Other Antidiabetic Drugs Added to Metformin Monotherapy in Diabetic Retinopathy Progression: A Real World-Based Cohort Study.
    Chung YR; Ha KH; Kim HC; Park SJ; Lee K; Kim DJ
    Diabetes Metab J; 2019 Oct; 43(5):640-648. PubMed ID: 30877707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensification with dipeptidyl peptidase-4 inhibitor, insulin, or thiazolidinediones and risks of all-cause mortality, cardiovascular diseases, and severe hypoglycemia in patients on metformin-sulfonylurea dual therapy: A retrospective cohort study.
    Wong CKH; Man KKC; Shi M; Chan EW; Ho CW; Tse ETY; Wong ICK; Lam CLK
    PLoS Med; 2019 Dec; 16(12):e1002999. PubMed ID: 31877127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data.
    Ha KH; Kim B; Choi H; Kim DJ; Kim HC
    Diabet Med; 2017 Sep; 34(9):1235-1243. PubMed ID: 28523719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between Add-On Dipeptidyl Peptidase-4 Inhibitor Therapy and Diabetic Retinopathy Progression.
    Kang EY; Kang C; Wu WC; Sun CC; Chen KJ; Lai CC; Chen TH; Hwang YS
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34203446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
    Ou HT; Chang KC; Li CY; Wu JS
    Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users.
    Gamble JM; Thomas JM; Twells LK; Midodzi WK; Majumdar SR
    Medicine (Baltimore); 2016 Jun; 95(26):e3995. PubMed ID: 27368005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin combined with dipeptidyl peptidase-4 inhibitors or metformin combined with sulfonylureas in patients with type 2 diabetes: A real world analysis of the South Korean national cohort.
    Cho YY; Cho SI
    Metabolism; 2018 Aug; 85():14-22. PubMed ID: 29530797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin-Based Therapies and Diabetic Retinopathy: Real-World Evidence in Older U.S. Adults.
    Wang T; Hong JL; Gower EW; Pate V; Garg S; Buse JB; Stürmer T
    Diabetes Care; 2018 Sep; 41(9):1998-2009. PubMed ID: 30012674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of dipeptidyl peptidase IV inhibitors, thiazolidinedione, and sulfonylurea on osteoporosis in patients with type 2 diabetes: population-based cohort study.
    Yang BR; Cha SH; Lee KE; Kim JW; Lee J; Shin KH
    Osteoporos Int; 2021 Sep; 32(9):1705-1712. PubMed ID: 33594487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study.
    Lee SJ; Ha KH; Lee JH; Lee H; Kim DJ; Kim HC
    PLoS One; 2019; 14(2):e0211959. PubMed ID: 30742667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sodium-glucose cotransporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on diabetic retinopathy and its progression: A real-world Korean study.
    Chung YR; Ha KH; Lee K; Kim DJ
    PLoS One; 2019; 14(10):e0224549. PubMed ID: 31658289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Important differences in the durability of glycaemic response among second-line treatment options when added to metformin in type 2 diabetes: a retrospective cohort study.
    Mamza J; Mehta R; Donnelly R; Idris I
    Ann Med; 2016; 48(4):224-34. PubMed ID: 26982210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National trends in metformin-based combination therapy of oral hypoglycaemic agents for type 2 diabetes mellitus.
    Kim J; Park S; Kim H; Je NK
    Eur J Clin Pharmacol; 2019 Dec; 75(12):1723-1730. PubMed ID: 31475315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany-A retrospective analysis of real-world data.
    Dombrowski S; Kostev K; Jacob L
    Osteoporos Int; 2017 Aug; 28(8):2421-2428. PubMed ID: 28455750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.
    Wang T; Yang JY; Buse JB; Pate V; Tang H; Barnes EL; Sandler RS; Stürmer T
    Diabetes Care; 2019 Nov; 42(11):2065-2074. PubMed ID: 31471377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan.
    Chang CY; Yeh YH; Chan YH; Liu JR; Chang SH; Lee HF; Wu LS; Yen KC; Kuo CT; See LC
    Cardiovasc Diabetol; 2017 Dec; 16(1):159. PubMed ID: 29258504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl peptidase-4 inhibitor use and risk of diabetic retinopathy: A population-based study.
    Kim NH; Choi J; Kim NH; Choi KM; Baik SH; Lee J; Kim SG
    Diabetes Metab; 2018 Sep; 44(4):361-367. PubMed ID: 29752167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
    Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
    Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.